| A group of physicians at Thomas Jefferson
University is conducting a research study to determine the effects of Neoral®
(cyclosporine, USP) MODIFIED on pregnancy in women who have psoriasis or
rheumatoid arthritis. Our purpose is to enroll all women with either psoriasis
or rheumatoid arthritis who are pregnant and are taking Neoral® (cyclosporine,
USP) MODIFIED. One of our goals is to gather information to determine the
safety of using Neoral® (cyclosporine, USP) MODIFIED during pregnancy in
this patient population.
 If
you have questions or would like more information about the Neoral® Pregnancy
Registry for Psoriasis and Rheumatoid Arthritis, please call us at 1-888-522-5581
or e-mail at neoral.registry@jefferson.edu.
Principal Investigator:
Vincent
T. Armenti, MD,PhD
Professor of Surgery
Division of Transplant Surgery
|
![[Jefferson]](http://www.jefferson.edu/images/Jeff1.gif){kind=small}
![[Hospital]](http://www.jefferson.edu/images/hospital1.gif){kind=small}
![[Jefferson Pulse]](http://www.jefferson.edu/images/pulse1.gif){kind=small}
![[Employment]](http://www.jefferson.edu/images/employment1.gif){kind=small}
![[Contact Us]](http://www.jefferson.edu/images/contact1.gif){kind=small}
![[Search]](http://www.jefferson.edu/images/search1.gif){kind=small}
![[News]](http://www.jefferson.edu/images/news1.gif){kind=small}
